Cargando…

A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation

BACKGROUND: This study is a systematic evaluation of a novel tobacco product, electronic cigarettes (ECIGs) using a two-site, four-arm, 6-month, parallel-group randomized controlled trial (RCT) with a follow-up to 9 months. Virginia Commonwealth University is the primary site and Penn State Universi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Alexa A., Cobb, Caroline O., Yingst, Jessica M., Veldheer, Susan, Hrabovsky, Shari, Yen, Miao-Shan, Foulds, Jonathan, Eissenberg, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778292/
https://www.ncbi.nlm.nih.gov/pubmed/26941050
http://dx.doi.org/10.1186/s12889-016-2792-8
_version_ 1782419437451739136
author Lopez, Alexa A.
Cobb, Caroline O.
Yingst, Jessica M.
Veldheer, Susan
Hrabovsky, Shari
Yen, Miao-Shan
Foulds, Jonathan
Eissenberg, Thomas
author_facet Lopez, Alexa A.
Cobb, Caroline O.
Yingst, Jessica M.
Veldheer, Susan
Hrabovsky, Shari
Yen, Miao-Shan
Foulds, Jonathan
Eissenberg, Thomas
author_sort Lopez, Alexa A.
collection PubMed
description BACKGROUND: This study is a systematic evaluation of a novel tobacco product, electronic cigarettes (ECIGs) using a two-site, four-arm, 6-month, parallel-group randomized controlled trial (RCT) with a follow-up to 9 months. Virginia Commonwealth University is the primary site and Penn State University is the secondary site. This RCT design is important because it is informed by analytical work, clinical laboratory results, and qualitative/quantitative findings regarding the specific ECIG products used. METHODS: Participants (N = 520) will be randomized across sites and must be healthy smokers of >9 cigarettes for at least one year, who have not had a quit attempt in the prior month, are not planning to quit in the next 6 months, and are interested in reducing cigarette intake. Participants will be randomized into one of four 24-week conditions: a cigarette substitute that does not produce an inhalable aerosol; or one of three ECIG conditions that differ by nicotine concentration 0, 8, or 36 mg/ml. Blocked randomization will be accomplished with a 1:1:1:1 ratio of condition assignments at each site. Specific aims are to: characterize ECIG influence on toxicants, biomarkers, health indicators, and disease risk; determine tobacco abstinence symptom and adverse event profile associated with real-world ECIG use; and examine the influence of ECIG use on conventional tobacco product use. Liquid nicotine concentration-related differences on these study outcomes are predicted. Participants and research staff in contact with participants will be blinded to the nicotine concentration in the ECIG conditions. DISCUSSION: Results from this study will inform knowledge concerning ECIG use as well as demonstrate a model that may be applied to other novel tobacco products. The model of using prior empirical testing of ECIG devices should be considered in other RCT evaluations. TRIAL REGISTRATION: TRN: NCT02342795, registered December 16, 2014.
format Online
Article
Text
id pubmed-4778292
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47782922016-03-05 A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation Lopez, Alexa A. Cobb, Caroline O. Yingst, Jessica M. Veldheer, Susan Hrabovsky, Shari Yen, Miao-Shan Foulds, Jonathan Eissenberg, Thomas BMC Public Health Study Protocol BACKGROUND: This study is a systematic evaluation of a novel tobacco product, electronic cigarettes (ECIGs) using a two-site, four-arm, 6-month, parallel-group randomized controlled trial (RCT) with a follow-up to 9 months. Virginia Commonwealth University is the primary site and Penn State University is the secondary site. This RCT design is important because it is informed by analytical work, clinical laboratory results, and qualitative/quantitative findings regarding the specific ECIG products used. METHODS: Participants (N = 520) will be randomized across sites and must be healthy smokers of >9 cigarettes for at least one year, who have not had a quit attempt in the prior month, are not planning to quit in the next 6 months, and are interested in reducing cigarette intake. Participants will be randomized into one of four 24-week conditions: a cigarette substitute that does not produce an inhalable aerosol; or one of three ECIG conditions that differ by nicotine concentration 0, 8, or 36 mg/ml. Blocked randomization will be accomplished with a 1:1:1:1 ratio of condition assignments at each site. Specific aims are to: characterize ECIG influence on toxicants, biomarkers, health indicators, and disease risk; determine tobacco abstinence symptom and adverse event profile associated with real-world ECIG use; and examine the influence of ECIG use on conventional tobacco product use. Liquid nicotine concentration-related differences on these study outcomes are predicted. Participants and research staff in contact with participants will be blinded to the nicotine concentration in the ECIG conditions. DISCUSSION: Results from this study will inform knowledge concerning ECIG use as well as demonstrate a model that may be applied to other novel tobacco products. The model of using prior empirical testing of ECIG devices should be considered in other RCT evaluations. TRIAL REGISTRATION: TRN: NCT02342795, registered December 16, 2014. BioMed Central 2016-03-03 /pmc/articles/PMC4778292/ /pubmed/26941050 http://dx.doi.org/10.1186/s12889-016-2792-8 Text en © Lopez et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Lopez, Alexa A.
Cobb, Caroline O.
Yingst, Jessica M.
Veldheer, Susan
Hrabovsky, Shari
Yen, Miao-Shan
Foulds, Jonathan
Eissenberg, Thomas
A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation
title A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation
title_full A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation
title_fullStr A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation
title_full_unstemmed A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation
title_short A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation
title_sort transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778292/
https://www.ncbi.nlm.nih.gov/pubmed/26941050
http://dx.doi.org/10.1186/s12889-016-2792-8
work_keys_str_mv AT lopezalexaa atransdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT cobbcarolineo atransdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT yingstjessicam atransdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT veldheersusan atransdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT hrabovskyshari atransdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT yenmiaoshan atransdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT fouldsjonathan atransdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT eissenbergthomas atransdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT lopezalexaa transdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT cobbcarolineo transdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT yingstjessicam transdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT veldheersusan transdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT hrabovskyshari transdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT yenmiaoshan transdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT fouldsjonathan transdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation
AT eissenbergthomas transdisciplinarymodeltoinformrandomizedclinicaltrialmethodsforelectroniccigaretteevaluation